金陵药业噁拉戈利片获批开展Ⅲ期临床研究

Core Viewpoint - Jinling Pharmaceutical has received approval for the Phase III clinical trial of Orelagol, a GnRH antagonist for treating moderate to severe pain associated with endometriosis, indicating a significant step in its product development pipeline [1] Group 1: Company Overview - Jinling Pharmaceutical's main business includes pharmaceutical and medical device manufacturing, as well as health care services [1] - The company’s product range covers cardiovascular, iron supplements, gastrointestinal medications, and oncology supportive drugs [1] - The company has a strong competitive advantage in the iron supplement market with its key product, Succinic Acid Iron Tablets [1] Group 2: Recent Financial Performance - In the first half of 2025, the company reported revenue of 1.6 billion yuan, a decrease of 6.6% year-on-year [1] - The net profit attributable to shareholders was 48.33 million yuan, down 14.08% year-on-year [1] - The net profit excluding non-recurring items was 35.51 million yuan, reflecting a decline of 21.6% year-on-year [1] Group 3: Business Strategy and Innovation - The company emphasizes the synergy between its pharmaceutical and health care platforms to support stable and high-quality development [2] - The pharmaceutical segment plays a crucial role, focusing on growth stabilization, cost reduction, structural adjustment, and capacity enhancement [2] - R&D investment increased by 20.51% year-on-year to 45.34 million yuan, with progress in product development and patent applications [2]